Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the company has entered into an asset purchase agreement to acquire the global digital pathology business of Tampa, Florida-based Inspirata, Inc. Upon completion of this agreement, Inspirata's Dynamyx® digital pathology technology, employees and customers will become part of Fujifilm. The addition of digital pathology will expand Fujifilm’s robust Synapse® Enterprise Imaging offering to enable the integration of pathology images and data into a healthcare organization’s electronic health record system and help to streamline care delivery for oncology patients and provider teams. 

Building off the success of its established partnership with Inspirata, this acquisition marks Fujifilm’s full-scale, global entry into the largely unpenetrated digital pathology market, where 85% of U.S., 86% of European, and 90% of Asian healthcare organizations are still running on analog.

“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” says Teiichi Goto, president and CEO, representative director, FUJIFILM Corporation. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”

Dynamyx is an open, vendor-agnostic, end-to-end digital pathology solution. Dynamyx’s software capabilities include using whole slide images from multiple scanning vendors to create an easier path for more pathology labs to digitize and realize the benefits of faster patient results, centralized imaging records, and enterprise access to images for all clinicians. It is installed in medical facilities that handle large volumes of pathological images across multiple lab locations, allowing the use of their preferred mix of laboratory and diagnostic technologies with confidence of full compatibility. According to a recent DeciBio article, Dynamyx is shown to have one of the largest partnership networks in the digital pathology space.

It will become part of Fujifilm’s Synapse Enterprise Imaging portfolio – an award-winning suite of healthcare IT solutions that unify imaging, data access and workflows across the health system. With the addition of digital pathology, Fujifilm will offer one of the most comprehensive enterprise imaging portfolios on the market consisting of a Best in KLAS winning VNA, Radiology PACS, and Cardiology PACS, as well as an enterprise information system, cloud services, and 3D advanced visualization. Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development.

“A $320 million global industry in 2021 projected to reach $640 million by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” says Henry Izawa, president and CEO, FUJIFILM Healthcare Americas Corporation.

These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”

Henry Izawa, President and CEO, FUJIFILM Healthcare Americas Corporation

“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the UK,” says Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president FUJIFILM Medical Systems Europe. “We've received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”

Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. With a specialty as image and data heavy as pathology, digitization is key. Pathologists, clinicians, patients, researchers and biopharma companies alike may see benefits such as improved and more efficient workflows, enhanced collaboration, remote and centralized interpretation, faster patient results, overall cost savings, ROI, and increased precision of diagnosis. Fujifilm’s existing partnership with Inspirata has demonstrated success in implementing these benefits for several global healthcare organizations.

Dynamyx has been cleared and/or approved for use in the U.S., Canada, Europe and the UK by each region’s regulatory agency. Dynamyx technology ownership and ongoing development and engineering will be led in the U.S. by FUJIFILM Healthcare Americas Corporation and licensed to other regions. Timing for the completion of the transaction is subject to closing conditions and is scheduled for early 2023. Terms of the agreement have not been disclosed.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    FUJIFILM Corporation. (2022, December 20). Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20221220/Fujifilm-announces-asset-purchase-agreement-with-Inspirata-Inc-to-acquire-the-companye28099s-digital-pathology-business.aspx.

  • MLA

    FUJIFILM Corporation. "Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20221220/Fujifilm-announces-asset-purchase-agreement-with-Inspirata-Inc-to-acquire-the-companye28099s-digital-pathology-business.aspx>.

  • Chicago

    FUJIFILM Corporation. "Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business". News-Medical. https://www.news-medical.net/news/20221220/Fujifilm-announces-asset-purchase-agreement-with-Inspirata-Inc-to-acquire-the-companye28099s-digital-pathology-business.aspx. (accessed April 24, 2024).

  • Harvard

    FUJIFILM Corporation. 2022. Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20221220/Fujifilm-announces-asset-purchase-agreement-with-Inspirata-Inc-to-acquire-the-companye28099s-digital-pathology-business.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Fujifilm integrates AI software to help identify bone trauma at POC (Point-of-Care)